DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Ray KK, Vallejo-Vaz AJ, Ginsberg HN. et al.
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Atherosclerosis 2019;
288: 194-202
DOI: 10.1016/j.atherosclerosis.2019.06.896.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.